+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Liver Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Liver Cancer Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 187 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716289
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver cancer diagnostics market is rapidly advancing, shaped by clinical innovation, technological transformation, and evolving policy environments. Senior executives need a clear understanding of how integrated approaches are enabling earlier detection, precision care, and new operational priorities across healthcare systems worldwide.

Market Snapshot

The liver cancer diagnostics market grew from USD 10.70 billion in 2025 to USD 11.38 billion in 2026. It is expected to continue growing at a CAGR of 6.81%, reaching USD 16.97 billion by 2032. Market momentum is driven by increased disease incidence, shifts in detection technology, and growing demand for advanced diagnostic pathways. Strategic clinical adoption, regional adaptation, and the integration of digital diagnostics all play a central role in market trajectory and opportunity.

Scope & Segmentation

  • Disease Stages: Early stage and advanced stage clinical needs define adoption priorities, with early detection emphasizing noninvasive surveillance and advanced stages focusing on molecular profiling and precise phenotyping for targeted therapy selection.
  • End-User Environments: Diagnostic solutions are deployed across ambulatory care, diagnostic centers, hospitals, and research laboratories. Each setting has distinct requirements for workflow integration, data management, and throughput efficiencies.
  • Test Modalities: Modalities include biomarkers (subdivided into genetic markers such as ctDNA and microRNA tests, and protein markers like AFP and DCP assays), biopsy (core needle, fine needle aspiration), genetic testing (next-generation sequencing, PCR analysis), and imaging (CT, MRI, PET, ultrasound).
  • Technology Platforms: Key technologies comprise CT, MRI, PET, and ultrasound, now increasingly augmented by artificial intelligence and digital workflow integration.
  • Regions: The market encompasses the Americas, Europe, Middle East & Africa, and Asia-Pacific, each shaped by unique payer models, regulatory frameworks, and diagnostic infrastructure.

Liver Cancer Diagnostics Market: Key Takeaways

  • Clinical adoption is accelerating through integration of molecular assays, liquid biopsies, and next-generation imaging—enabling nuanced disease characterization and improved patient management pathways.
  • Diagnostic protocols are evolving toward noninvasive, high-sensitivity approaches for high-risk and early-stage patient cohorts, supporting personalized surveillance and earlier intervention.
  • Multidisciplinary care models and reimbursement frameworks are dynamically reassessing value, with increasing payer focus on outcomes and the ability to reduce the need for invasive procedures.
  • Collaboration between test developers, device manufacturers, clinical laboratories, and technology providers is streamlining interoperability, evidence generation, and product validation for broader market access.
  • Organizations that align diagnostic solutions with specific end-user and regional workflows, and that demonstrate clinical utility with real-world evidence, are most likely to scale successfully in diverse healthcare environments.

Tariff Impact on Operational Strategy

Recent United States tariff adjustments in 2025 have influenced global procurement and supply chain strategies for liver cancer diagnostics. Cost fluctuations in imported diagnostic components and reagents have led industry players to diversify supplier bases, invest in regional sourcing, and accelerate local manufacturing partnerships. Larger health systems with purchasing consortia have managed these shifts through long-term contracting and volume planning, while smaller laboratories and diagnostic centers have had to weigh investments in new technologies against optimizing existing assets. These tariff-driven pressures reinforce the need for flexible, interoperable diagnostic platforms and proactive supply chain risk management to stabilize operational costs and sustain technology access.

Methodology & Data Sources

This analysis combined structured expert interviews with clinical and operational leaders, systematic review of peer-reviewed literature, and in-depth technology mapping. Comparative capability assessment, supply chain risk analysis, and scenario-based adoption evaluation informed findings. All insights underwent expert validation for transparency, consistency, and reproducibility.

Why This Report Matters

  • Enables executives to align innovation, evidence generation, and operational strategy for accelerated commercial adoption of advanced diagnostic solutions.
  • Supports procurement, payer, and regulatory decision-making by detailing how regional factors influence market entry and patient access.
  • Provides actionable intelligence for supply chain planning and product development, ensuring resilience amid evolving policy and technological landscapes.

Conclusion

Integrated advances in liver cancer diagnostics—combining molecular, imaging, and data-driven methodologies—are improving disease detection and care precision. Emerging operational priorities and regional dynamics highlight the need for clinically validated, scalable, and supply-resilient solutions that enable better outcomes across care settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Liver Cancer Diagnostics Market, by Disease Stage
8.1. Advanced Stage
8.2. Early Stage
9. Liver Cancer Diagnostics Market, by Test Type
9.1. Biomarkers
9.1.1. Genetic Markers
9.1.1.1. ctDNA Tests
9.1.1.2. MicroRNA Tests
9.1.2. Protein Markers
9.1.2.1. AFP Tests
9.1.2.2. DCP Tests
9.2. Biopsy
9.2.1. Core Needle Biopsy
9.2.2. Fine Needle Aspiration
9.3. Genetic Testing
9.3.1. Next-Generation Sequencing
9.3.2. PCR Analysis
10. Liver Cancer Diagnostics Market, by Technology
10.1. CT Scan
10.2. MRI
10.3. PET
10.4. Ultrasound
11. Liver Cancer Diagnostics Market, by End User
11.1. Ambulatory Care
11.2. Diagnostic Centers
11.3. Hospitals
11.4. Research Laboratories
12. Liver Cancer Diagnostics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Liver Cancer Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Liver Cancer Diagnostics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Liver Cancer Diagnostics Market
16. China Liver Cancer Diagnostics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Amgen inc
17.7. Argon Medical Devices, Inc.
17.8. Bayer AG
17.9. Becton, Dickinson and Company
17.10. Bio-Rad Laboratories, Inc.
17.11. bioMérieux SA
17.12. Boston Scientific Corporation
17.13. Danaher Corporation
17.14. Epigenomics AG
17.15. F. Hoffmann-La Roche Ltd.
17.16. Hologic, Inc.
17.17. Illumina, Inc.
17.18. QIAGEN N.V.
17.19. Siemens Healthineers AG
17.20. Sysmex Corporation
17.21. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 123. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 129. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 130. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 144. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 146. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 147. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 148. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 149. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 150. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 166. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 167. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 168. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 170. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 171. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 174. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 175. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 176. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 177. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 178. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 179. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 180. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 194. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 195. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 196. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 197. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 198. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 199. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 200. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 201. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 204. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 205. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 206. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 207. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 208. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 209. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 210. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 211. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 214. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 215. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 216. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 217. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 218. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 219. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 220. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 221. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 235. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 236. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 237. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 238. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 239. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 240. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 241. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 242. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Liver Cancer Diagnostics market report include:
  • Abbott Laboratories
  • Amgen inc
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Boston Scientific Corporation
  • Danaher Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.38 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.97 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), by End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), by Region and Segment Forecasts, 2025-2033 - Product Image

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), by End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), by Region and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Liver Cancer Diagnostics Market Report 2025 - Product Image

Liver Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Liver Cancer Diagnostics - Global Strategic Business Report - Product Image

Liver Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 275 Pages
  • Global
From

About the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies used to detect and diagnose liver cancer. These tests can include imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). Additionally, blood tests, biopsies, and other laboratory tests may be used to diagnose liver cancer. The Liver Cancer Diagnostics market is highly competitive, with a range of companies offering products and services. These include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Hologic. Other companies in the market include Agilent Technologies, Bio-Rad Laboratories, and Cepheid. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.